We use cookies on our websites to ensure the proper functioning of the website and to help provide the best user experience.
By continuing to use our site, you agree to the use of cookies. Learn more about cookies here.


Campylobacter infection and treatment

Campylobacter is a Gram-negative bacterium frequently found in both humans and animals.

It normally inhabits the intestinal tract of warm-blooded animals such as poultry and cattle. Consequently foods of animal origin can become contaminated with Campylobacter. The majority of Campylobacter infections are acquired through the consumption of contaminated water, raw and inadequately pasteurised milk, and undercooked meats, particularly poultry1,2.

Symptoms of campylobacteriosis include diarrhoea, abdominal pain, fever, headache and nausea. Infections are generally mild, but can be fatal among very young children, elderly and those already suffering from another serious disease such as AIDS1. In some cases, complications can be severe and chronic in nature, such as Guillan-Barré syndrome, rheumatoid arthritis and irritable bowel syndrome2,3.

In persons with compromised immune systems, Campylobacter occasionally spreads to the bloodstream and causes a serious life-threatening infection4,5. Campylobacter enteritis is frequently self-limiting, with a gradual resolution of symptoms over several days. Fluid and electrolyte replacement constitutes the cornerstone of treatment6. Antimicrobial therapy is warranted only for patients with severe disease or those at high risk for severe disease, such as those with immune systems severely weakened from medications or other illnesses4. Because the greatest therapeutic benefit occurs when antimicrobial therapy is started early, the rapid diagnosis of Campylobacter infection is clinically relevant6.

Early and prompt identification of the reason for acute infectious gastroenteritis can reduce the severity of disease and help to administer timely and appropriate treatment and to implement infection control precautions in healthcare settings, such as isolation of the patients.

When prompt diagnosis matters

Orion GenRead® Campylobacter is a molecular test intended for detection of Campylobacter species C. jejuni, C. coli and C.lari directly from faecal samples collected from patients suspected of having Campylobacter infection.

Orion GenRead Campylobacter is a ready-to-use kit which offers its users fast and accurate results. The test kit is used together with the Orion GenRead Instrument and is suitable for laboratories of various settings and sizes.

The Orion GenRead system is based on SIBA technology, Orion Diagnostica’s proprietary isothermal nucleic acid amplification technique.

Orion GenRead Campylobacter





Published October 24, 2016

1. World Health Organization. (2011). Campylobacter. Fact sheet No255. [Cited 10 Aug 2016]. Available from: http://www.who.int/mediacentre/factsheets/fs255/en/
2. World Health Organization. (2012). The global view of campylobacteriosis: report of an expert consultation. Geneva: WHO; 2012. [Cited 10 Aug 2016]. Available from: http://apps.who.int/iris/bitstream/10665/80751/1/9789241564601_eng.pdf
3. European centre for disease prevention and control. Annual epidemiological report 2013. Reporting on 2011 surveillance data and 2012 epidemic intelligence data. Stockholm: ECDC; 2013. [Cited 10 Aug 2016]. Available from: http://ecdc.europa.eu/en/publications/Publications/annual-epidemiological-report-2013.pdf
4. Centerts for Disease Control and Prevention. 2014. Campylobacter. [Cited 4 July 2016]. Available from: http://www.cdc.gov/foodsafety/diseases/campylobacter/index.html
5. Man, S.M. (2011). The clinical importance of emerging Campylobacter species. Nature Reviews, Gastroenterology & Hepatology, 8, 699-685; published online 25 October 2011; doi:10.1038/nrgastro.2011.191
6. Allos, B.M., Iovine, N.M. & Blaser, M.J. (2015). Campylobacter jejuni and related species, in Mandell, Douglas, and Bennett’s Principles and Practice of Infectious diseases, Eight edition, Chapter 218, p. 2485-2493.